Previous close | 17.48 |
Open | 17.79 |
Bid | 18.13 x 200 |
Ask | 18.20 x 200 |
Day's range | 17.34 - 18.32 |
52-week range | 8.92 - 24.50 |
Volume | |
Avg. volume | 387,414 |
Market cap | 822.648M |
Beta (5Y monthly) | 1.69 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.52 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 23.13 |
BioLife Solutions (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business
BioLife Solutions Inc (NASDAQ:BLFS) Chief Marketing Officer Todd Berard has sold 10,000 shares of the company on April 15, 2024, according to a recent SEC Filing.